Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in endometrial cancer and ovarian cancer, respectively
Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for its experimental sickle cell therapy, and will halt development of
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, suggesting that the therapy is durable beyond the
Novocure announced Monday morning that its electrical fields wearable device combined with chemotherapy passed a late-stage trial in pancreatic cancer, and the biotech now plans